COMPANION ANIMAL VACCINE MARKET ANALYSIS

Regional Analysis

Global Companion Animal Vaccine Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global companion animal vaccine market over the forecast period. North America is estimated to hold 48.3% of the market share in 2023. The global companion animal vaccine market is expected to witness significant growth in the coming years, driven by the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement, and increased awareness. The increasing prevalence of neurological disorders is contributing to the growth of the companion animal vaccine market in the North America region. For instance, Merck Animal Health, a division of Merck & Co., a U.S.-based pharmaceutical company, announced on  September 2022, the launch of the NobivacIntra-Trac Oral BbPi vaccine, which is indicated to be used for the dual prevention of two major canine respiratory pathogens. The new product launches and approvals of vaccines are expected to increase the number of vaccine produced in the U.S., thereby driving demand for veterinary vaccines in the U.S.

Based on Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, the North America region is expected to dominate the market over the forecast period, and this is attributed to the increasing heathcare funding by government.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa